Last viewed: TEVJF

Prices are updated after-hours

Health technology TEVJF Nasdaq

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVJF | News | $12.37 -24.22% 380

|

Health Technology

(0.0% 1d) (0.0% 1m) (48.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (83.09% volume)
Earnings Calendar:
Market Cap: $ 14,739,472,016
http://www.teva.co.il
Sec Filling | Patents | n/a employees

(IL) Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

cancer infectious disease pain relief israel cardiovascular

add to watch list Paper trade email alert is off

Press-releases

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Published: 2024-04-19 (Crawled : 10:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M

|

| 2.48% | O: 1.16% H: 7.28% C: 1.3%
KMDA | News | $5.05 -0.98% -0.99% 27K

|

Health Technology

| 1.76% | O: 1.76% H: 0.0% C: 0.0%
humira biosimilar approved for agreement

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Published: 2024-04-16 (Crawled : 21:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M

|

Health Technology

| 1.96% | O: -0.04% H: 0.28% C: -0.16%
stelara fda biosimilar approval teva

Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M

|

Health Technology

| -0.62% | O: -0.53% H: 0.0% C: -1.24%
NVS | $94.36 1.93% 0.0% 2.3M

|

Health Technology

| 0.17% | O: -1.46% H: 0.0% C: 0.0%
PHG | $19.98 0.0% 540K

|

Health Technology

| -3.34% | O: -1.21% H: 0.0% C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M

|

Health Technology

| -1.85% | O: -1.19% H: 0.52% C: -0.17%
VRNA | $15.82 -1.74% -1.83% 640K

|

Health Technology

| -0.51% | O: 1.65% H: 2.43% C: 0.87%
reach treatment research market

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M

|

Health Technology

| -2.8% | O: 0.23% H: 0.23% C: -1.28%
austedo for meeting

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M

|

Health Technology

| -7.15% | O: -1.01% H: 2.04% C: 1.17%
ajovy for teva trial migraine china results

Central Nervous System (CNS) Stimulant Drugs Market size is set to grow by USD 6.48 billion from 2023-2027, Rise in incidence of CNS disorders boost the market, Technavio
Published: 2024-04-10 (Crawled : 09:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K

|

Health Technology

| -9.51% | O: -100.0% H: NaN% C: Infinity%
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| -1.65% | O: -0.01% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K

|

Health Technology

| -2.16% | O: -1.67% H: 0.0% C: 0.0%
ALPMY | $9.47 -1.11% 520K

|

| -9.26% | O: -0.29% H: 0.0% C: -1.97%
VTRS A | $11.25 1.17% 1.16% 4.7M

|

Health Technology

| -4.01% | O: -0.6% H: 1.03% C: 0.52%
TMO | News | $544.78 0.6% 0.0% 1.7M

|

Health Technology

| -7.54% | O: -2.01% H: 0.0% C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M

|

Health Technology

| -1.37% | O: -1.16% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -2.59% | O: -0.32% H: 0.0% C: 0.0%
JAZZ | $109.96 0.63% 0.63% 760K

|

Health Technology

| -4.92% | O: -1.71% H: 0.57% C: 0.37%
disorders system set market

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
Published: 2024-04-09 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M

|

Health Technology

| -9.44% | O: -0.7% H: 0.07% C: -0.92%
first conference teva financial results

Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| 0.01% | O: 2.24% H: 0.0% C: -0.8%
AZNCF | News | $138.24 -4.19% 800

|

Health Technology

| 2.24% | O: -3.43% H: 6.21% C: 6.21%
VTRS A | $11.25 1.17% 1.16% 4.7M

|

Health Technology

| -4.66% | O: -0.25% H: 1.1% C: -0.17%
NVS | $94.36 1.93% 0.0% 2.3M

|

Health Technology

| -1.49% | O: -0.05% H: 0.43% C: -0.27%
BMY | $48.93 1.3% 0.0% 10M

|

Health Technology

| -4.66% | O: -0.08% H: 0.04% C: -0.35%
BHC | $8.69 1.05% 0.0% 2.9M

|

Health Technology

| -16.52% | O: 0.38% H: 0.0% C: -7.27%
ABBV | $166.41 1.06% 0.0% 5.5M

|

Health Technology

| -0.9% | O: 0.77% H: 1.63% C: 0.35%
SNY | News | $46.32 2.05% 2.01% 3.3M

|

Health Technology

| -1.33% | O: 0.84% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M

|

Health Technology

| 1.63% | O: 0.18% H: 0.3% C: 0.19%
eczema dermatitis set therapeutics market

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Published: 2024-04-04 (Crawled : 00:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M

|

Health Technology

| -8.92% | O: -0.42% H: 0.0% C: 0.0%
candidate biosimilar global for teva agreement

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
Published: 2024-04-03 (Crawled : 11:00) - globenewswire.com
ALVO | News | $13.23 2.64% 2.57% 1.7M

|

| 15.96% | O: 2.98% H: 0.17% C: -0.43%
KMDA | News | $5.05 -0.98% -0.99% 27K

|

Health Technology

| -6.65% | O: -0.18% H: 2.16% C: 0.9%
audio

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-028015	4	2024-03-07	2024-03-05	Sell	M	52320	0
0000950170-24-028015	4	2024-03-07	2024-03-05	Sell	M	21387	21390
0000950170-24-028015	4	2024-03-07	2024-03-06	Sell	S	77550	203691
0000950170-24-028015	4	2024-03-07	2024-03-05	Buy	M	21387	281241
0000950170-24-028015	4	2024-03-07	2024-03-05	Buy	M	52320	259854
0000950170-24-026008	4	2024-03-05	2024-03-04	Buy	A	200892	200892
0000950170-24-026008	4	2024-03-05	2024-03-03	Sell	M	67231	201693
0000950170-24-026008	4	2024-03-05	2024-03-04	Sell	S	31061	123295
0000950170-24-026008	4	2024-03-05	2024-03-03	Buy	M	67231	154356
0000950170-24-015601	4	2024-02-15	2024-02-13	Sell	M	6630	0
0000950170-24-015601	4	2024-02-15	2024-02-13	Buy	M	6630	105792
0000950170-24-011009	4	2024-02-05	2024-02-01	Sell	S	31766	10676

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M

|

EGOX | $0.0515 43.06% 30.1% 330M

|

OLB 4 | $0.33 -14.95% 25.53% 840K

|

Technology Services

NVFY | $2.77 31.28% 23.83% 33M

|

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M

|

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M

|

Distribution Services

INSG | $3.03 25.21% 20.13% 330K

|

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K

|

WLGS | $0.59 18.0% 17.9% 2.3M

|

ASNS | $0.828 21.75% 17.86% 18K

|

Last 48 Hours Insiders Buying

RXO P 200000 | $19.37 2.32% 0.0% 1M

|

| 23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M

|

| 22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K

|

Health Technology

| 22:30
BCDA P 2750 | $0.377 -1.4% 97K

|

Health Technology

| 22:00
RMCF | $3.67 3.38% 3.27% 11K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar